NCT05377957 2026-04-15
PROQEM
Leiden University Medical Center
Active not recruiting
Clinical Trials
28 trialsNCT06414590 2026-04-14
Neoadjuvant Tebentafusp for Uveal Melanoma
Thomas Jefferson University
Phase 2 Recruiting
NCT05170334 2026-04-06
Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT03025256 2026-04-02
Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT05628883 2026-04-02
Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT05524935 2026-04-01
Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT06861647 2026-04-01
iSITE
The Wellcome Sanger Institute
Completed
NCT06961357 2026-03-31
Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Recruiting
NCT07276386 2026-03-31
Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT07501117 2026-03-30
Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma
Herlev Hospital
Phase 1 Not yet recruiting
NCT06075589 2026-03-19
Psychoeducation for Uveal Melanoma
Jonsson Comprehensive Cancer Center
Phase NA Active not recruiting
NCT06550674 2026-03-19
IGCMU
Centre Jean Perrin
Phase NA Recruiting
NCT04119024 2026-03-17
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Phase 1 Recruiting
NCT02068586 2026-03-16
Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma
Thomas Jefferson University
Phase 2 Active not recruiting
NCT01046487 2026-03-13
PALANGI3
Centre Oscar Lambret
Phase 1 Completed
NCT07364474 2026-03-11
Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver
Massachusetts General Hospital
Phase NA Recruiting
NCT02858869 2026-03-09
Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases
Emory University
Phase 1 Completed
NCT04792463 2026-03-09
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
Ohio State University
Recruiting
NCT06070012 2026-02-27
Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
University of Pittsburgh
Phase 2 Recruiting
NCT03417739 2026-02-25
A Phase II Study of BVD-523 in Metastatic Uveal Melanoma
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT06627244 2026-02-23
Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma
University of Miami
Phase 2 Recruiting
NCT02517736 2026-02-17
O-Mel-Sora
University Hospital, Caen
Phase 2 Completed
NCT04552223 2026-02-11
Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma
University of Miami
Phase 2 Completed
NCT06432660 2026-02-06
PROMPT
Duke University
Active not recruiting
NCT05607095 2026-02-04
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT04645680 2026-01-30
DIET
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT01983748 2026-01-28
Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma
University Hospital Erlangen
Phase 3 Completed
NCT03865212 2026-01-28
Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma
Mayo Clinic
Phase 1 Terminated